Search CatalystAlert
Search for companies, drugs, and catalysts
Search CatalystAlert
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No catalyst events have been recorded for this drug yet.
0 competitors in Leukemia, Chronic Myelogenous
View Full LandscapeNo patent data available. Pre-approval drugs may not have Orange Book listings.
Scemblix
Scemblix is indicated for the treatment of adult patients with Philadelphia chromosome positive chronic myeloid leukaemia in chronic phase (Ph+ CML CP) previously treated with two or more tyrosine kinase inhibitors (see section 5.1).
Influenza
Heart Transplantation
Non-alcoholic Fatty Liver Disease (NAFLD)
Meningococcal Meningitis
Axial Spondyloarthritis